カテゴリ： GlobalData, アメリカ, 企業調査

Scynexis Inc (SCYX)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Scynexis Inc (SCYX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C3388
◆発行会社（調査会社）：GlobalData
◆発行日：2018年8月
◆ページ数：78
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Scynexis Inc (Scynexis) is a pharmaceutical company that discovers, develops and commercializes novel anti-infective for various therapeutic needs. The company provides pipeline products such as SCY-078, is used for invasive fungal infections; SCY-635, is used for the treatment of Hepatitis C (HCV); SCYX-7158, is used for sleeping sickness; SCY-641, is for human health, among others. Its SCY-078 is a chemical class of glucan synthase inhibitors that blocks target in infectious fungi by interfering with the assembly of the fungal cell wall and prevents the growth of fungal species. Scynexis provides its drug pipeline solutions to pharmaceutical, healthcare and life sciences companies, among others. The company develops products by using technology platforms such as enfumafungin platform, cyclophilin platform and calcineurin platform, among others. Scynexis is headquartered in Jersey City, New Jersey, the US.

Scynexis Inc (SCYX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Scynexis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Scynexis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Scynexis Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Scynexis Raises Additional US$6 Million In Venture Financing 11
Partnerships 12
Scynexis Enters Into Co-Marketing Agreement With R-Pharm For SCY-078 12
Morria BioPharma Enters Into Co-Development Agreement With SCYNEXIS For MRX-4 13
Licensing Agreements 14
Scynexis Enters into Licensing Agreement with Waterstone Pharma for SCY-635 14
Equity Offering 15
Scynexis Prices Public Offering of Shares and Warrants for USD30 Million 15
Scynexis Raises USD22.5 million in Public Offering of Shares and Warrants 17
Scynexis Raises USD41 Million in Public Offering of Shares 19
Scynexis Raises USD62 Million in IPO 21
Asset Transactions 23
Cypralis Acquires Cyclophilin Inhibitor Assets from Scynexis 23
Avista Pharma Acquires Contract Services Business from Scynexis 24
Accelrys Acquires Hit Explorer Operating System From Scynexis 26
Scynexis Inc – Key Competitors 27
Scynexis Inc – Key Employees 28
Scynexis Inc – Locations And Subsidiaries 29
Head Office 29
Recent Developments 30
Financial Announcements 30
Aug 09, 2018: SCYNEXIS announces second quarter 2018 financial results 30
May 08, 2018: SCYNEXIS Reports First Quarter 2018 Financial Results and Provides Company Update 32
Mar 13, 2018: SCYNEXIS Reports Full Year 2017 Financial Results 34
Nov 07, 2017: SCYNEXIS Reports Third Quarter 2017 Financial Results and Provides Company Update 36
Aug 08, 2017: SCYNEXIS Reports Second Quarter 2017 Financial Results and Provides Company Update 38
May 08, 2017: SCYNEXIS Reports First Quarter 2017 Financial Results 40
May 08, 2017: SCYNEXIS Q1 net loss decreases 41
Mar 13, 2017: SCYNEXIS Reports Full Year 2016 Financial Results and Provides Company Update 42
Corporate Communications 44
Jan 26, 2017: SCYNEXIS Announces Appointment of Industry Veteran Marion McCourt to its Board of Directors 44
Product News 45
10/05/2017: SCYNEXIS Presents New Data Further Supporting SCY-078 as a Potential Treatment for Aspergillus and Candida Infections at IDWeek 2017 45
07/18/2018: The World Health Organization Recognizes New Antifungal Class by Granting “ibrexafungerp” to SCYNEXIS as the International Non-Proprietary Name for SCY-078 46
06/27/2018: SCYNEXIS Announces the Presentation of SCY-078 Data at the Teratology Society 58th Annual Meeting 47
06/15/2017: New Study Further Demonstrates In Vitro Activity of SCYNEXIS’ Lead Anti-Infective Candidate, SCY-078, Against Drug-Resistant Candida Fungal Strains 48
06/14/2018: SCYNEXIS to Present SCY-078 Data at Three Scientific Meetings in June/July 2018 49
06/11/2018: SCYNEXIS Presents SCY-078 Data at ASM Microbe 2018 50
06/05/2017: Eight Presentations at ASM Microbe 2017 Further Highlight the Strong Antifungal Effect and Promising Safety Profile of Lead Anti-Infective Candidate SCY-078 51
05/24/2018: SCYNEXIS to Present SCY-078 Data at ASM Microbe 2018 52
04/21/2017: SCYNEXIS to Host a Conference Call to Discuss Lead Anti-Infective Candidate SCY-078 Data Presented at 27th ECCMID 53
04/10/2018: SCYNEXIS to Present SCY-078 Data at the 28th European Congress of Clinical Microbiology and Infectious Disease 54
Product Approvals 55
Mar 02, 2017: SCYNEXIS delays initiation of new clinical studies using the IV formulation of SCY-078 at FDAs request 55
Clinical Trials 56
Jul 10, 2018: SCYNEXIS Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in Vulvovaginal Candidiasis 56
Jun 06, 2018: SCYNEXIS Announces the Publication of Phase 1 Study Results for SCY-078 in The Journal of Clinical Pharmacology 58
May 01, 2018: SCYNEXIS’s Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention of Recurrent VVC 59
Apr 23, 2018: SCYNEXIS Data Presentations at ECCMID 2018 Show SCY-078 Potent and Synergistic Antifungal Activity Against Aspergillus and Pneumocystis 60
Mar 20, 2018: SCYNEXIS Presents Data at Superbugs and Superdrugs 2018 61
Feb 01, 2018: SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of Aspergillus Infections at AAA 2018 62
Jan 04, 2018: SCYNEXIS Provides Corporate and SCY-078 Pipeline Update 63
Sep 27, 2017: SCYNEXIS to Present Data on Lead Antifungal Candidate SCY-078 at IDWeek 2017 65
Aug 14, 2017: SCYNEXIS Presents New Data Supporting Oral SCY-078 for the Clinical Treatment of Vulvovaginal Candidiasis Infections at the 2017 IDSOG Annual Meeting 66
Aug 03, 2017: SCYNEXIS Announces Initiation of Dosing in Phase 2 Study Evaluating Oral SCY-078 in Vulvovaginal Candidiasis 67
May 24, 2017: Eight SCY-078 Data Presentations at ASM Microbe 2017 Confirm Potential of SCYNEXIS’ Lead Agent to Combat Serious and Life-threatening Fungal Infections 68
May 11, 2017: Potent in vitro Activity of SCYNEXIS SCY-078 Against Multidrug-Resistant Fungal Pathogen Candida auris Further Confirmed in an in vitro Study Conducted by the Centers for Disease Control and Prevention 70
May 08, 2017: SCYNEXIS Provides Update on IV Formulation Development Status 72
Apr 25, 2017: Eight Data Presentations at ECCMID Showcase the Broad Applicability of SCYNEXIS’ Lead Anti-infective Candidate SCY-078 73
Apr 12, 2017: SCYNEXIS to Present SCY-078 Data on Novel Lead Anti-infective Candidate at 27th European Congress of Clinical Microbiology and Infectious Diseases 75
Feb 24, 2017: First Systematic Study of Deadly, Antibiotic-Resistant Fungus Reported 77
Appendix 78
Methodology 78
About GlobalData 78
Contact Us 78
Disclaimer 78

List of Tables
Scynexis Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Scynexis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Scynexis Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Scynexis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Scynexis Raises Additional US$6 Million In Venture Financing 11
Scynexis Enters Into Co-Marketing Agreement With R-Pharm For SCY-078 12
Morria BioPharma Enters Into Co-Development Agreement With SCYNEXIS For MRX-4 13
Scynexis Enters into Licensing Agreement with Waterstone Pharma for SCY-635 14
Scynexis Prices Public Offering of Shares and Warrants for USD30 Million 15
Scynexis Raises USD22.5 million in Public Offering of Shares and Warrants 17
Scynexis Raises USD41 Million in Public Offering of Shares 19
Scynexis Raises USD62 Million in IPO 21
Cypralis Acquires Cyclophilin Inhibitor Assets from Scynexis 23
Avista Pharma Acquires Contract Services Business from Scynexis 24
Accelrys Acquires Hit Explorer Operating System From Scynexis 26
Scynexis Inc, Key Competitors 27
Scynexis Inc, Key Employees 28

List of Figures
Scynexis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Scynexis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Scynexis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Scynexis Inc (SCYX)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • BARMER GEK：企業の戦略的SWOT分析
    BARMER GEK - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Briggs & Stratton Corporation：企業の戦略・SWOT・財務分析
    Briggs & Stratton Corporation - Strategy, SWOT and Corporate Finance Report Summary Briggs & Stratton Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Halozyme Therapeutics Inc (HALO)：医療機器：M&Aディール及び事業提携情報
    Summary Halozyme Therapeutics Inc (Halozyme) is a biotechnology company that develops and commercializes novel recombinant human enzymes to provide innovative products for cancer, dermatology, diabetes and drug delivery markets. The company’s marketed product, Hylenex is an agent for drug and fluid …
  • Culp Inc (CULP)：企業の財務・戦略的SWOT分析
    Culp Inc (CULP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • TIM SpA (TIT)：企業の財務・戦略的SWOT分析
    TIM SpA (TIT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • EnBW Energie Baden-Wurttemberg AG (EBK)：企業の財務・戦略的SWOT分析
    EnBW Energie Baden-Wurttemberg AG (EBK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Austevoll Seafood ASA：企業の戦略・SWOT・財務情報
    Austevoll Seafood ASA - Strategy, SWOT and Corporate Finance Report Summary Austevoll Seafood ASA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Pro Petroleum Inc：企業の戦略的SWOT分析
    Pro Petroleum Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Bank of the Ryukyus, Ltd.：企業の戦略・SWOT・財務情報
    Bank of the Ryukyus, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Bank of the Ryukyus, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Illovo Sugar Africa Pty Ltd：企業の戦略的SWOT分析
    Illovo Sugar Africa Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • The Hain Celestial Group, Inc.：戦略・SWOT・企業財務分析
    The Hain Celestial Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Hain Celestial Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • PowerFilm, Inc.：企業の戦略的SWOT分析
    PowerFilm, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Genedata AG：医療機器：M&Aディール及び事業提携情報
    Summary Genedata AG (Genedata) is a healthcare technology company that transforms data into software solutions. The company delivers enterprise solutions for data analytics that streamline research and development workflows and improve research productivity. Its products include genedata biologics, …
  • Aarti Drugs Ltd (AARTIDRUGS)：企業の財務・戦略的SWOT分析
    Summary Aarti Drugs Ltd (ADL), a subsidiary of Aarti Group of Industries is a contract manufacturer of pharmaceutical products that offers therapeutic products, ingredients, bulk drugs, and chemicals. The company's products include active pharmaceutical ingredients, pharma intermediates, and special …
  • Adaptive Biotechnologies Corp：医療機器：M&Aディール及び事業提携情報
    Summary Adaptive Biotechnologies Corp (Adaptive) specializes in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. The company’s product portfolio comprises immunoSEQ and clonoSEQ. It provides immunosequencing platform to laboratories for conductin …
  • Baylor Scott & White Health：製薬・医療：M&Aディール及び事業提携情報
    Summary Baylor Scott & White Health (Baylor Scott & White) is a not-for-profit healthcare service provider that offers medical care services. The organization offers medical education, medical services and conducts medical research. It offers medical services in the areas of emergency care, cancer c …
  • TRC Companies Inc：電力：M&Aディール及び事業提携情報
    Summary TRC Companies Inc (TRC Companies) is a construction service provider that offers engineering, consulting and construction management. The company’s services include air quality management, power generation, power delivery engineering, integrity management, energy efficiency, coal ash managem …
  • Unicharm Corporation (8113)：企業の財務・戦略的SWOT分析
    Unicharm Corporation (8113) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Edisun Power Europe AG (ESUN)：企業の財務・戦略的SWOT分析
    Summary Edisun Power Europe AG (Edisun Power) is a solar power producer. The company finances, develops and operates solar power plants in various European countries. It offers technical studies, legal and financial studies, custom design, installation, work monitoring, and operation and maintenance …
  • Transmetro Corporation Limited：企業の戦略・SWOT・財務分析
    Transmetro Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Transmetro Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆